While low GWP propellants represent exciting change, drug developers will face challenges in the transition to low carbon pMDIs, such as costly reformulations and supply chain pressures.
To address this, it is important to partner with an experienced CDMO that is investing in its sustainable capabilities to help support change in the industry.
To explore our insights on the role of CDMOs in this transition, and our commitment to expanding our low GWP manufacturing capabilities, read our contribution to Drug Development and Delivery’s 2024 Respiratory Drug Development eBook.
